Flunil 20 contains the active ingredient Fluoxetine, which belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It is primarily prescribed to treat a variety of mental health conditions, including:
Depression: Flunil 20 is commonly used to alleviate the symptoms of major depressive disorder, which may include persistent feelings of sadness, loss of interest or pleasure in daily activities, changes in appetite and sleep patterns, and difficulty concentrating.
Obsessive-Compulsive Disorder (OCD): It can help manage the recurring, distressing thoughts (obsessions) and repetitive behaviors (compulsions) associated with OCD.
Panic Disorder: Flunil 20 may be prescribed to mitigate panic attacks and symptoms of panic disorder, such as sudden and overwhelming fear or discomfort.
Bulimia Nervosa: It can be part of the treatment plan for individuals with bulimia, helping to control binge-eating episodes and reduce the cycle of overeating and purging.
Premenstrual Dysphoric Disorder (PMDD): Some individuals with severe PMDD may benefit from Flunil 20 to alleviate mood-related symptoms before their menstrual periods.
Flunil 20 works by increasing the availability of serotonin, a neurotransmitter in the brain that plays a crucial role in regulating mood, emotions, and behavior. By enhancing serotonin levels, the medication helps restore a better balance in the brain, leading to symptom improvement in the conditions mentioned above.
It's important to note that Flunil 20 should only be taken under the supervision of a qualified healthcare professional, as dosages and treatment duration can vary based on individual needs and the specific condition being treated. Additionally, potential side effects and interactions with other medications should be discussed with a healthcare provider. Patients are advised to follow their doctor's guidance and not make any changes to their medication regimen without consulting a healthcare professional.
Dr. Aadil Hussain Bhat
Scientist, UCLA School of Dentistry, Los Angeles, California USA
Dr. Aida Adlimoghaddam
Clinical Research Scientist, Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada